Baudax Bio currently holds 9.31
M in liabilities.
The firm shows a Beta (market volatility) of 1.197, which signifies a somewhat significant risk relative to the market. Let's try to break down what Baudax's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Baudax Bio will likely underperform. Even though it is essential to pay attention to
Baudax Bio historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards foreseeing any stock's
future performance is to check both, its past performance charts as well as the business as a whole, including all available
technical indicators. Baudax Bio exposes twenty-seven different technical indicators, which can help you to evaluate its performance.
Baudax Bio has an expected return of -2.35%. Please be advised to confirm Baudax Bio
jensen alpha,
potential upside, as well as the
relationship between the Potential Upside and
accumulation distribution to decide if
Baudax Bio performance from the past will be repeated at some point in the near future.
We determine the current worth of Baudax BioInc using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Baudax BioInc based exclusively on its
fundamental and basic
technical indicators. By analyzing Baudax BioInc's
financials, quarterly and monthly indicators, and related drivers such as
dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of
Baudax BioInc's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Baudax BioInc. We calculate exposure to Baudax BioInc's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Baudax BioInc's related companies.
Watch out for price decline
Please consider monitoring Baudax BioInc on a daily basis if you are holding a position in it. Baudax BioInc is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Baudax BioInc stock to be traded above the $1 level to remain listed. If Baudax BioInc stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Baudax BioInc Investment Alerts
Baudax investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Baudax BioInc performance across your portfolios.Please check all
investment alerts for Baudax
Baudax BioInc Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare Baudax value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Baudax BioInc competition to find
correlations between indicators driving the intrinsic value of Baudax.
Baudax BioInc Gross Profit
Baudax BioInc Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Baudax BioInc previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Baudax BioInc Gross Profit growth over the last 10 years. Please check Baudax BioInc's
gross profit and other
fundamental indicators for more details.
A Deeper Perspective
This firm reported the previous year's revenue of 756
K. Net Loss for the year was (66.25
M) with loss before overhead, payroll, taxes, and interest of (1.24
M).
| 2019 | 2020 | 2021 | 2022 (projected) |
Return on Invested Capital | 4.26 | 27.0 | 31.05 | 33.51 | Return on Average Equity | 0.77 | 1.96 | 2.25 | 1.93 |
Baudax Bio Earnings Before Interest Taxes and Depreciation Amortization USD is fairly stable at the moment. Further, Baudax Bio Average Equity is fairly stable at the moment. Baudax Bio Earnings Before Interest Taxes and Depreciation Amortization USD is decreasing over the last 6 years. The previous year's value of Baudax Bio Earnings Before Interest Taxes and Depreciation Amortization USD was -89,568,869. Further, Baudax Bio Average Equity is fairly stable at the moment.
The case for Baudax Bio slide maybe to hold
Current potential upside is at 10.39. Baudax Bio is displaying above-average volatility over the selected time horizon. Investors should scrutinize Baudax Bio independently to ensure intended market timing strategies are aligned with expectations about Baudax Bio volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Baudax Bio's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Baudax Bio's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Baudax Bio Implied Volatility
Baudax Bio's implied volatility exposes the market's sentiment of Baudax Bio stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Baudax Bio's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Baudax Bio stock will not fluctuate a lot when Baudax Bio's options are near their expiration.
While many other companies in the biotechnology industry are either recovering or due for a correction, Baudax Bio may not be performing as strong as the other in terms of long-term growth potentials. Taking everything into account, as of the 12th of March 2022, we see that Baudax Bio almost mirrors the market. The company is
fairly valued with
low probability of bankruptcy within the next 24 months. Our final 90 days buy-sell recommendation on the company is
Cautious Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Baudax BioInc. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com